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Abstract 
The maintenance and expansion of the cells required for formation of tissue-engineered 
cartilage has, to date, proven difficult. This is, in part, due to the initial solid phase extracellular 
matrix demanded by the cells inhabiting this avascular tissue. Herein, we engineer an 
innovative alginate-fibronectin microfluidic-based carrier construct (termed a chondrobag) 
equipped with solid phase presentation of growth factors that support skeletal stem cell 
chondrogenic differentiation while preserving human articular chondrocyte phenotype. Results 
demonstrate biocompatibility, cell viability, proliferation and tissue-specific differentiation for 
chondrogenic markers SOX9, COL2A1 and ACAN. Modulation of chondrogenic cell 
hypertrophy, following culture within chondrobags loaded with TGF-b1, was confirmed by 
down-regulation of hypertrophic genes COL10A1 and MMP13. MicroRNAs involved in the 
chondrogenesis process, including miR-140, miR-146b and miR-138 were observed. Results 
demonstrate the generation of a novel high-throughput, microfluidic-based, scalable carrier that 
supports human chondrogenesis with significant implications therein for cartilage repair-based 
therapies.  
Keywords: biofabrication, droplet-based microfluidics, stem cells, chondrogenesis, hydrogels, fibronectin  
 
1. Introduction 
Cartilage lesions represent an important technical challenge 
for tissue engineering given the avascular nature of this tissue, 
which often leads to defective intrinsic healing.1 Unattended 
cartilage damage can result in osteoarthritis (OA), the most 
prevalent chronic pathology of joints.1, 2 Defective articular 
cartilage and alterations made to the state of bone at joint 
margins for instance, are among a diverse set of signs and 
symptoms associated with OA.3 Chondrocytes, derived from 
the native tissue, have been examined as an apparent cell 
source of the formation of neocartilage.  
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Over the last decades, interest in stem cells for tissue 
engineering applications has noticeably increased, given their 
capacity for self-renewal and multi-lineage differentiation.4 
Chondrocytes or chondroprogenitors, derived from stromal 
progenitors, need to be guided in the formation of native 
hyaline cartilage, to avert dedifferentiation and, critically, to 
ensure the generation of pre-eminent tissue reconstruction in 
vivo that resembles the complex cellular and extracellular 
matrix (ECM) make-up in the native tissue. In addition, the 
generated tissue must be permissive to typical load-bearing 
while providing long-lasting joint performance.5 A wealth of 
literature suggests micromass or pellet culture models, offer 
an appropriate method for generating small-scale micron sized 
tissues of engineered neocartilage in vitro. Furthermore, more 
advanced cartilage-like tissues exhibiting improved 
mechanical properties have been made exploiting 3D models 
for cell proliferation and differentiation.6 These systems 
facilitate interactions between the cell and the requisite 
cellular environment/matrix.7 However, these 3D systems still 
display an overall lack of homogeneity in cell responses 
related to the necrotic cores,8 that could be assigned to a list of 
contributing factors including: (i) the non-physiological 
closely compacted cells that are formed during initial stages 
of culture, (ii) the existence of necrotic cores enclosed by in 
vitro/ex vivo cell clusters as a consequence of high cell 
number, (iii) sub-standard physiological culture conditions 
and, (iv) diffusion limitations by uncontrolled establishment 
of chemical gradients throughout samples.9 
Recent studies have explored high throughput strategies for 
micro-tissue modeling.10, 11 Thus, microfluidics offers 
significant potential for the generation of high-throughput cell 
culture prototypes, presenting unparalleled spatio-temporal 
control on the requisite micro-environmental conditions.12, 13 
To this objective, we present an experimental droplet-based 
microfluidic device for the fabrication and the culture of 3D 
micromass constructs of mature chondrocytes and skeletal 
stem cells (SSCs) generated under constant laminar flow, 
termed ‘chondrobags’. Chondrobags are highly mono-
dispersed, pearl-lace interlinking hydrogel-based structures 
with pearl and lace subunit sizes ranging from 100 and 150 
µm. We note that SSCs are a bone marrow derived multipotent 
mesenchymal stromal cell (MSCs) population with the 
established propensity for skeletal regeneration.14 
It is clear that materials used for cartilage tissue engineering 
significantly affect the pattern of the gene expression of the 
chondrocyte population therein.15 Mimicking the hydrated 
environment of native cartilage, hydrogels offer an attractive 
approach for the development of cartilage regenerative 
strategies. Hydrogels are made by crosslinking naturally 
derived polymers, such as collagen and alginate, as well as 
polymers manufactured, such as polyethylene glycol and 
polyacrylamide. These polymer networks are crosslinked 
hydrophilic systems that are able to retain high volumes of 
fluid without dissolving. This allows construction of a 
microenvironment for cells, which takes on the appearance of 
native tissue through facilitation of waste and nutrients 
exchange.16 Furthermore, hydrogels offer a strategy for the 
homogeneous encapsulation of cells of interest in comparison 
to numerous reported scaffolds. Critically, the mechanical 
properties of hydrogels, such as viscoelasticity, typically, can 
be fine-tuned to mimic those found in the native cartilage.17 
Alginate is a biocompatible material that is used to form 
microporous hydrogels.18 The permeable nature of the alginate 
hydrogel allows diffusion of nutrients, molecules and 
facilitates communication and contact between cells, 
providing a rich ECM-like environment that can support cell 
viability.19 Indeed, a number of studies have shown that 
MSCs-laden alginate hydrogels can support 
chondrogenesis.19-21 
Naturally found alginate polymers offer good 
hydrophilicity and allow ionic crosslinking. However, 
alginate hydrogels lack intrinsic cell adhesion domains, which 
diminish their biological activity and subsequently hamper 
their use in tissue engineering.22 Approaches to overcome this 
limitation have centred on the incorporation of molecules such 
as Arg-Gly-Asp (RGD)-based peptides to facilitate integrin 
binding.16 The display of an RGD sequence in alginate 
hydrogels provides a strategy for control over the phenotype 
of participating chondrocytes, osteoblasts, and MSCs.23 The 
functional RGD peptide is a cell adhesion motif, found in 
ECM proteins including fibronectin (FN)24 and suggested to 
positively contribute to the chondrogenesis of MSCs, 
although, the effect is controversial and dependent on 
application.25 FN has been denoted to initiate the cellular 
signalling of chondrocyte differentiation26 and is critical in 
orchestration of the assembly of further ECM proteins 
including collagen.27 Furthermore, the down-regulation of FN 
can alter cell morphology and shape resulting in reduced 
chondrogenic differentiation.28 
Cationic molecules such as transforming growth factor beta 
(TGF-β) display affinity towards the negatively charged 
alginate molecules by way of the Coulombic interaction and 
can be freed from alginate with slow kinetics.29 In addition, 
the 12th–14th type III repeats of fibronectin (FN III12–14) 
bind to the TGF-β superfamily with high affinity.30 The TGF-
β superfamily is made up of three type of isoforms (TGF-β1, 
TGF-β2, and TGF-β3); however, exclusively, TGF-β1 and 
TGF-β3 are relevant for stem cell chondrogenic 
differentiation.31, 32 TGF-β3 displays a higher chondrogenic 
promise as compared to TGF-β1, leading to enhanced 
differentiation.33 However, it remains unclear, if this TGF-β3 
enhanced differentiation is correlated with higher 
responsiveness for chondrocyte hypertrophy. 
We have generated an innovative alginate-FN micron-sized 
subunit carrier for chondrogenesis – chondrobags. This novel 
system allows high-throughput fabrication of reproducible 
microgels with precise control over the density of embedded 
cells, shape and mono-dispersity. The chondrobags 
incorporate FN to immobilise growth factors and encapsulated 
cells while bypassing the diffusion limit for oxygen and 
nutrition given the chondrobag size. In addition, using pearl-
lace interlinking hydrogel-based structures, chondrobags can 
be used for alternative microfluidic-based bioprinting.34 The 
alginate-FN chondrobags presenting TGF-β1 in solid phase 
provide a favourable chondrogenic microenvironment for 
specific differentiation of in situ cultured skeletal stem cells 
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(SSCs) and human articular chondrocytes (HACs), with 
implications therein for future tissue engineering applications.  
2. Materials and Methods 
2.1 Human bone marrow derived SSCs isolation and 
culture 
Bone marrow was sourced from a patient undertaking total 
hip replacement surgery at Spire Hospital in conjunction with 
the full ethical consent and approval from the hospital ethics 
committee (LREC 194/99/w, 27/10/10), through which 
informed patient consent was attained. All procedures making 
use of human tissue and cells were carried out in agreement 
with stipulated recommendations and regulations. Bone 
marrow (male 70 years of age) was acquired and used for 
isolating and culturing human bone marrow derived SSCs as 
previously detailed.35 Washed bone marrow mixture was 
sieved through a 70 µm cell filter and separated using 
Lymphoprep™ (Lonza). Prior to a wash step with magnetic 
activated cell sorting (MACS) buffer (BSA and EDTA in 
PBS), harvested mononuclear cells were incubated in 
blocking buffer (α-MEM, 10% human serum, 5% fetal calf 
serum (FCS) and 10 mg/mL bovine serum albumin). Cells 
were incubated in 1 mL of hybridoma-based STRO-1 
antibody and following a wash with MACS buffer were re-
suspended in 1 mL containing 800 µL MACs buffer and 200 
µL rat anti-mouse IgM microbeads (Miltenyi Biotec Ltd). A 
second MACS harvest for target cells was followed by 
washing with MACS buffer. Isolated target cells were washed 
and re-suspended in α-MEM containing 10% FCS and 1% 
penicillin/streptomycin (P/S) and cultured in tissue culture 
flasks. 
2.2 Human articular chondrocytes isolation and culture 
Femoral head was acquired from a male patient (61 years 
of age) undergoing total hip replacement surgery at 
Southampton General Hospital, in conjunction with the full 
ethical consent and approval from the hospital ethics 
committee (LREC 194/99/w, 27/10/10), with informed patient 
consent attained. The OA femoral head was classified as end 
stage OA (3–5 OARSI). The articular cartilage was dissected 
from the femoral head and sliced into small sections within 6 
hours post-surgery. Cartilage sections were incubated for 30 
minutes at 37 °C in 10% trypsin (Sigma Aldrich) followed by 
15 minutes in 0.1% hyaluronidase (Sigma Aldrich) following 
a wash with PBS. This trypsin-hyaluronidase step was 
followed by a further wash and incubation for 12–15 hours at 
37°C in 1% collagenase B (Roche Diagnostics). The 
suspension containing the digested articular chondrocytes was 
filtered through a 70 µm filter. Isolated chondrocytes were re-
suspended in DMEM/F12 containing 5% FCS, 1% insulin-
transferrin-selenium (ITS) (Sigma-Aldrich), 1% P/S and 0.2% 
of ascorbic acid (Sigma-Aldrich), and placed into tissue 
culture flasks. 
2.3 Microfluidic fabrication 
Co-flow focusing glass capillary device (Figure 1 A and B) 
for pearl-lace like microgel production developed in this 
study, was first reported by Witte et al.34 Glass capillaries (< 
1.8 mm, TST150-6 and TW100-6, World precision 
instruments, Inc.) were tapered to desired hole sizes (0.04 - 
0.07 mm) using a micropipette puller (P-97, Sutter 
Instruments) and centrally aligned in a square capillary of 2 
mm ID (World precision instruments, Inc.). Sigmacote 
(Sigma-Aldrich) was used to modify the glass surface 
generating a hydrophobic layer. Capillaries were fixed on a 
cover-slide and using soft tubing, coupled with controllable 
syringe pumps (Harvard Apparatus). 
2.3 Cell encapsulation 
Both SSCs and HACs populations were initially treated for 
40 min with collagenase IV (200 µg/mL) in α-MEM prior to 
detachment from culture plates using 0.025% (w/v) Trypsin–
EDTA with 0.05% glucose for 10 min at 37°C. To prepare a 
2% alginate mixture, both cell types were individually re-
suspended in the corresponding basal media and subsequently 
mixed 1:1 together with a medium viscosity 4% (w/v) sodium 
alginate (Sigma-Aldrich, UK) solution. FN sourced from 
human plasma (Sigma) was added to the mixture to give a 
final concentration 20 µg/mL. The water-based alginic cell 
mixture entered the microfluidic device through one of the two 
channels of a theta-shaped capillary, while leaving the other 
channel for 200 mM calcium chloride aqueous solution. 
Mineral oil (Sigma-Aldrich, UK) with 2% Span 80 (Sigma-
Aldrich, UK) was introduced as the continuous phase through 
a square-shaped housing capillary for dispersing the two 
water-based solutions as they mixed within the flow focusing 
regime. Pre-warmed basal culture media was used as the 
collection solution for formed hydrogels.  This step was 
followed by a 100 mM calcium chloride wash before culturing 
in either basal media or chondrogenic media comprising 10 
nM dexamethasone, 100 µM ascorbic acid, 10 µg/mL ITS and 
10 ng/mL of either TGF-β1 or TGF-β3 (Peprotech) at 37°C 
and 5% CO2 in a humidified atmosphere. Media 
(chondrogenic differentiation media and basal media) was 
changed every two days until the end of the experiment at day 
28. 
2.4 Viability assay 
Viability studies were carried out following incubation of 
the cell-laden hydrogels for an hour at 37°C in a 100 mM 
calcium chloride solution containing 2 µM calcein and 2 µM 
ethidium homodimer-1 (EthD-1) (Viability/Cytotoxicity Kit, 
Life Technologies, UK). For the viability calculation, the 
total number of live cells (stained green) were analysed in 
comparison to the total number of cells (stained either green 
or red). Viability was expressed as a percentage of the 
control. The hardware and software from EVOS Fl Colour 
Cell Imaging System were used for assigning the stained 
samples (green for live and red for dead cells). For 
measuring the pixel intensity of the fluorescence signals, 
sample images were processed using ImageJ software 
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version 1.51 (100) and later graphed using GraphPad Prism 
(version 8.0 software). 
2.5 RNA isolation and quantification 
Chondrobags were prepared with a PBS wash at the end of 
the culturing period, prior to a 10 minutes incubation at 37°C 
incubation with 1 mL of dissolving buffer (0.055M sodium 
citrate, in 0.03M EDTA, 0.15M NaCl, pH 6.8) at 1,000 rpm. 
This step was followed by centrifugation at 10,000 rpm for 
two minutes, a PBS wash and another round of centrifugation 
at 14,500 rpm for two minutes. 350 mL of RLT Plus Buffer 
was used to lyse the pellets formed by the cells. The lysed cell 
mixture was added to 540 mL RNA-free water and 10 mL 
Protease K solution (Qiagen) and further incubated for 10 
minutes at 1000 rpm, 55°C. AllPrep DNA/RNA/miRNA 
Universal Kit (Qiagen) was used to isolate RNA from the 
samples following the guidelines by the manufacturer. 
Extracted RNA samples were quantified using a Nanodrop 
ND-1000 spectrophotometer. 
2.6 cDNA synthesis and mRNA expression analysis 
cDNA synthesis and real time quantitative PCR (qPCR) 
were carried out to analyse expression of mRNA in human 
SSCs and HACs. SuperScript® VILO cDNA Synthesis kit 
from Applied Biosystems was used for the synthesis of cDNA 
from sample containing isolated RNA. In brief, RNA was 
mixed with 2 µL 5X VILO™ reaction mix and 1 µL 10X 
SuperScript® enzyme. The mixture was subsequently 
incubated for 10 minutes at 25°C and, thereafter, by a further 
incubation at 42°C for 2 hours and 85°C for 5 minutes. qPCR 
was carried out with 10 µL of GoTaq master mix (Promega), 
5 µL of upH2O and 2 µL of reverse primer and 2 µL of forward 
primer for the gene of interest (primers listed in Table S1) and 
1 µL of sample containing isolated RNA. A 96 well-plate with 
each well containing a final mixture of 20 µL was later 
analysed using Applied Biosystems, 7500 Real Time PCR 
system. Acquired data was analysed using version 2.0.5 
program of Applied Biosystems 7500 System SDS. To 
identify the most stable housekeeping genes, standard 
optimisation procedures were performed. For normalising Ct 
(cross-over threshold) values for SSCs experiments, ACTB as 
the endogenous housekeeping gene and for HACs analysis, 
GAPDH were used respectively. The fold expression levels 
were calculated using delta-delta Ct method for each target 
gene. All the sample readouts as well as control (negative 
control with no cDNA) were analysed from triplicates.  
2.7 miRNA expression analysis 
RNA extracted as detailed in RNA isolation and 
quantification were assessed for expression of: miR-140, 
miR-146b or miR-138 using TaqMan® MiRNA Assays 
(Table S2). Every individual assay contained two primers: one 
primer was used for cDNA synthesis and the second primer 
was used to perform TaqMan q-PCR. For generating cDNA 
specific to each individual assay, specific miRNA from total 
RNA was generated with TaqMan® MiRNA Reverse 
Transcription Kit using a modified protocol from the 
manufacturer. In brief, a reaction mixture containing of 3.58 
µL upH2O, 0.75 µL 10X Buffer, 1.88 µL of RNase inhibitor, 
1.50 µL of RT primer, 0.08 µL of dNTPs and 10 ng of total 
RNA was made and incubated at 16°C for 30 minutes 
followed by 30 minutes at 42°C and further 5 minutes of 
incubation at 85°C before termination at 42°C. qPCR was 
carried out with 5 µL of TaqMan® Universal PCR Master Mix 
containing No AmpErase® UNG from Life technologies. The 
qPCR also included 3.34 µL of upH2O, 0.5 µL of TM primer 
and 0.8 µL of cDNA. A 96 well-plate containing this mixture 
was assessed using Applied Biosystems, 7500 Real Time PCR 
system and data gathered analysed using version 2.0.5 
program from Applied Biosystems 7500 System SDS. 
Standard optimisation procedures were performed to 
determine the appropriate housekeeping gene for the study of 
miRNA expression. For normalising Ct values, RNU44, was 
used as a housekeeping control RNA for miRNA. To calculate 
the fold expression level of each gene of interest, delta-delta 
Ct method was employed. All sample readouts, including 
negative controls (no cDNA), were analysed from duplicates. 
2.8 Enzyme Linked Immunosorbent Assay (ELISA) 
Solid Phase Sandwich ELISA for transforming Growth 
Factor Beta 1 and 3 release from the alginate construct were 
measured using Human TGF-β1 DuoSet ELISA (DY240-05) 
and Human TGF-β3 DuoSet ELISA (DY243) kits from R&D 
systems. 0.5 mL of alginate micro-beads (with and without FN 
at 20 µg/mL concentration) were soaked in 5 mL DMEM 
media containing either TGF-β1 or TGF-β3 at the 
concentration of 10 ng/mL overnight. The following day, 
micro-beads were placed into fresh media and samples for 
ELISA were taken at 1.5, 3, 6 and 24 hours. ELISA steps were 
carried out according to manufacturer’s instructions and the 
readouts performed using BioTek™ Synergy™ HT Multi-
Detection Microplate Reader.   
2.9 Histology 
Chondrobags were washed in 0.1 mM calcium chloride and 
fixed in 10% buffered formalin (neutral) prior to histological 
analysis. Specimens were dried using a series of graded 
ethanols, embedded in OCT (CellPath, UK) and cryo-
sectioned at 5 µm thickness. Dehydrated sections were 
collected onto APEs coated slides, air dried for 30 min and 
stored at -20°C until required for staining. For histological 
evaluation, sections were warmed at 37°C for 30 min and 
washed in RO water prior to staining with Alcian Blue/Sirius 
Red and Safranin O/Fast Green. Briefly, sections were stained 
with Weigert’s haematoxylin (A and B, 1:1 mix, Clin-Tech, 
UK) for 10 min prior to staining with 0.5% Alcian Blue 
(Sigma, UK) for 10 min, followed with molybdophosphoric 
acid (Sigma, UK) for 10 min and finally with Sirius Red (Clin-
Tech, UK) for an hour or were stained with Fast Green (FCF) 
solution for 5 minutes followed with Safranin O for 5 minutes. 
Between each staining step, slides were rinsed in a water bath 
for 1 min and drained. Slides were finally dehydrated through 
increasing ethanol concentrations and cleared in Histoclear 
(50%, 90%, 100%-1, 100%-2 ethanol and Histoclear-1 and 2 
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each for 30 seconds) before being mounted in p-xylene bis-
pyridinium bromide (DPX). Sections were observed using an 
Olympus dotSlide Virtual Microscopy System and images 
processed using Olympus OlyVIA 2.9 image analysis 
software.  
2.10 Statistical Analysis 
Data are presented as mean values and standard deviations 
(SD). Statistical analysis was performed by a one-way 
ANOVA, a Tukey post-hoc test and Student’s t test in 
GraphPad PrismTM 8 software with a level of significance of p 
< 0.1 marked by *, p < 0.05 marked by **, p < 0.001 marked 
by *** and p < 0.0001 marked by ****. 
3. Results and Discussion  
3.1 Microfluidic fabrication of mono-dispersed alginate-
fibronectin chondrobags and encapsulation of SSCs and 
HACs 
SSCs and HACs were encapsulated in pearl-lace like 
chondrobags using co-flow focusing glass capillary 
devices (Figure 1A–C and Supplementary Video 1 and 2). The 
design was optimised in respect to our previous report for 
encapsulation of a co-culture of MSCs and engineered 
bacteria.34  
The alginate-calcium composite is a diffusion-based 
hydrogel prepared by ionic cross-linking. Diffusion is a time-
dependent process and for this reason, fully homogeneous 
hydrogels can never be fully attained. Nevertheless, as the 
bead size is reduced, heterogeneity is reduced between formed 
hydrogels. As a consequence, Calcium diffusion occurred 
rapidly in the micro-sized beads leading to improved and high 
encapsulation efficiency (> 99%) (Figure 2A) within each 
microgel (Supplementary Video 2), leading to the generation 
of reproducible chondrobags (Figure 2B). The shape and size 
of the pearl-lace microgel construct chosen for this study 
provided efficient volume ratios between material and cell, 
eliminating the diffusion cap of 100 to 200 µm for the 
transport of oxygen, nutrients including ingress of vital 
biomolecules for encapsulated cells and facilitation of 
removal of cell waste.36 Chondrobags were generated at 5-10 
units per second within selected flow rates containing ~ 
2.6e+07 cells/mL (Figure 2C and Figure 2D). This resulted in 
cells residing in close proximity (~ 103 cells per chondrobag, 
Figure 2E) while facilitating nutrition and waste diffusing 
through the porous micro-structures of the alginate-FN 
hydrogel (Figure 2F).  
The superiority of 3D over 2D cultures to enhance stem 
cells functions are well documented, and the culture of SSCs 
in 3D has previously demonstrated enhanced stromal 
differentiation along the chondrogenic lineage.37  In contrast 
to 2D cultures, the culture of stem cells in 3D promoted 
enhanced cell-cell contact; facilitating exposure of cells to 
substrates with different physical properties including 
viscoelasticity and topography together with the display of 
assorted endogenous and exogenous ECM adhesion motifs for 
integrins.37 The application of droplet microfluidics for 3D 
micromass formation with HACs and SSCs, together with in 
situ fine temporal control over the constituents of biomaterials 
provided a powerful platform to deliver reproducible and, 
crucially, a high-throughput formation of functional 
micromass constructs.38, 39 Such a strategy has been 
undertaken using pluripotent stem cells.40-42  The 
incorporation of mechanical stress43 and hypoxia, 44 offer 
Figure 1. Droplet-based microfluidic setup, mono-dispersity and encapsulation. (A) Schematic representation of the microfluidic device and encapsulation 
of eukaryotic cells. (B) Image of the capillary based microfluidic device. (C) A snapshot of encapsulation of cells using the microfluidic device. Scale bar: 100 
µm. HACs: human articular chondrocytes, SSCs: Stro-1 enriched skeletal stem cells. 
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future approaches to enhance and further mimic the 
physiological environment to enhance chondrogenic 
differentiation.  
It has been shown that a bone-like physicochemical 
microenvironment can override chondroinductive signals 
including TGF-β1. The extracellular calcium-sensing receptor 
(CaSR) of human BM-derived MSCs has shown to become 
hyperstimulated by bone-like biomimetic hydroxyapatite 
(BBHAp).45 However, in this study, the calcium concentration 
used to gel the alginic acid was retained at the same level for 
all samples including the negative control constructs while 
studying the impact of TGF-β1 and TGF-β3 separately in FN 
containing chondrobags.  
Studies have established that the permeable structure of a 
scaffold can aid cell attachment, proliferation and 
differentiation, which can lead to generation of the phenotype 
of interest in a cell.32, 46 Chondrobags combine alginate and 
FN to provide a cost-effective facile strategy for three-
dimensional construct generation (18 - 36k chondrobags per 
hour) with a clear potential for cartilage tissue engineering. 
Correct porosity provides appropriate shape and 
environmental cues through mimicry of the chondrocyte 
lacunae to facilitate proliferation and differentiation. The 
favorable porosity, thin walls and excellent interconnectivity 
between pores of the hydrogel, contribute to nutrient and 
metabolic waste exchange. The induced condensation of 
HACS and SSCs in chondrobags is a significant milestone in 
comparison to current conventional scaffold-free systems 
requiring 3D culture, predominantly based on micromass 
pellets derived using centrifugation.8 The use of 
centrifugation, as an initial step, typically generates restrictive 
cell to cell and cell to ECM interactions, resulting in high 
variability in the time required to form 3D aggregates.9 In 
addition, traditional macro-pellet models are often too large 
and, typically, suffer from heterogeneity of cell phenotype and 
the formation of necrotic cores.8, 47 As shown in 
Supplementary Video 3, pearl-on-thread chondrobags can be 
used as a low-cost cell-laden bioprinting alternative. 
3.2 Skeletal cell viability, cell cluster and micro-mass 
formation in chondrobags 
The advantages of reduced shear stress experienced during 
cell encapsulation in chondrobags due to the channel design 
and low flow rates of this microfluidic design,34 contributed to 
high cell viability observed throughout the hydrogel. 
Evaluation of the cell viability of HACs and SSCs 
demonstrated the presence of live cells (>90%) with negligible 
necrotic cells present in the central regions of cell clusters in 
the chondrobags. Viability and biocompatibility of alginate-
FN chondrobags was confirmed 1, 3 and 24 hours following 
encapsulation and, crucially, at the conclusion of the studies, 
on day 28. Figure 3A-D demonstrate the level of viability 
observed following encapsulation at day 0 and at 28 days. For 
HACs, no differences in cell viability were observed between 
cells cultured in chondrogenic media with TGF-β1 or TGF-β3 
(Figure 3A-B). Enhanced HACs cell numbers were observed 
within chondrobags loaded with TGF-β3 with an average of 
11.8 cells per cluster, as compared to 8.3 cells per cluster in 
TGF-β1 and 1.8 cells per cluster for control samples (Figure 
3H). This variation is likely a consequence of differences in 
cell proliferation, given all the samples comprised the same 
initial cell density per chondrobag (Figure 2E). In addition to 
higher cell counts per cluster (1.4 times), the area of clusters 
in TGF-β3 was almost twice (1.9 times, normalised against 
Figure 2. Encapsulation efficiency, cell density and volume mono-dispersity of chondrobags. (A) Cell (HACs and SSCs) encapsulation efficiency. The 
cell counts at each time point are the result of 8 measurements sequentially acquired at 30-min intervals at room temperature for 2 h. (B) Volume distribution 
of produced chondrobags of two miscible fluid streams under laminar flow conditions using flow rates of 125 - 250 µL h-1 for the two inner phases and 3000 
µL h-1 for the outer phase. The median volume of the formed chondrobag was 0.16 mm3 with a RSD of 3.2%. (C) Cell concentrations used in this study. (D) 
Selected flow rates. (E) Cell concentration per chondrobag. (F) A snapshot of chondrobag filled with HAC. Scale bar: 100 µm. HACs: human articular 
chondrocytes, SSCs: Stro-1 enriched skeletal stem cells. 
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area of cell clusters in control sample) the size as compared to 
those stimulated with TGF-β1 (Figure 3G). Interestingly, this 
finding is consistent with the cell volume expansion of 
hypertrophic chondrocytes in the growth plate, as a 
consequence of an increase in organelles and increased 
metabolic activity.48 Mueller and collaborators have reported 
this to be the case for the enhancement of hypertrophy in MSC 
chondrogenesis.49  
SSCs encapsulated within chondrobags displayed a discrete 
increase in the numbers of necrotic cells following stimulation 
with TGF-β3 and TGF-β1, as compared to the control samples 
(Figure 3C-D). The micromass samples generated by SSCs 
within chondrobags, stimulated with TGF-β1 or TGF-β3, were 
noted to be more compact with no clear border (space) 
between cells within the same cluster/colony (Figure 3C and 
Figure 3. Skeletal cell viability, cell cluster and micro-mass formation in chondrobags. (A) Microscopy images of alginate-fibronectin (FN) chondrobags 
containing human articular chondrocytes (HACs) cultured in the presence of TGF-β1 or TGF-β3 for up to 28 days relative to untreated control. (B) HACs 
viability graph. (C) Microscopy images of alginate-FN chondrobags containing Stro-1 enriched skeletal stem cells (SSCs) cultured in the presence of TGF-β1 
or TGF-β3 for up to 28 days relative to untreated control. (D) SSCs viability graph. (E) Microscopy images of alginate-FN chondrobags containing HACs 
cultured in the presence of TGF-β1 or TGF-β3 for up to 28 days relative to untreated basal control. Individual cells are highlighted within a red circle. (F) 
Microscopy images of alginate-FN chondrobags containing SSCs cultured in the presence of TGF-β1 or TGF-β3 for up to 28 days relative to untreated basal 
control. Micro-masses are highlighted within a red circle. (G) Graph with area of SSCs and HACs cultured in the presence of TGF-β1 or TGF-β3 for up to 28 
days relative to untreated basal control. (H) Graph with number of cells found in clusters containing HACs after 28 days. Cells in green are stained with 
Calcein AM. Scale bar: 100 µm. The hydrogel was stained with Viability/Cytotoxicity Kit with viable cells in green (Calcein AM) and non-viable cells in red 
(Ethidium homodimer-1). Scale bar: 100 µm. N ≥ 5 – 10 microgels were analysed for each condition. Additional images can be found in Supplementary Figure 
1. 
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3F) as compared to the more dispersed HACs micromass 
samples (Figure 3A and 3E) after 28 days. The slight rise in 
the total number of necrotic cells in the centre of SSCs 
micromass samples is likely due, in part, to the larger size of 
the compact cell masses due to cell proliferation (7 and 5.1 
times larger cluster area, normalised against area of cell 
clusters, in control sample for TGF-β1 and TGF-β3, 
respectively. Figure 3G). Hence, hypoxia may have been 
induced with cells at the centre of the compact mass 
potentially deprived of nutrients/oxygen. These observations 
are significant given current literature has evidenced viability 
but limited cell proliferation.21  
 
3.3 Quantification of TGF-β in chondrobags 
Fibronectin (FN) is known to have specific interactions 
with a diverse range of GFs, such as PDGF, FGF, IGF, TGF-
β and others.30, 50 The extent of this interaction varies within 
members of each superfamily. Within the TGF-β superfamily, 
TGF-β1, BMP-2, and BMP-7 display a high measure of 
affinity to a domain containing the 12th to 14th type III copies 
of FN (FN III12–14). However, in comparison, TGF-β2, TGF-
β3, BMP-4, and BMP-6 did not exhibit notable binding to 
FN.30 Consistent with this finding, GF release studies in 
chondrobags demonstrated that alginate-FN microgels display 
a 4-fold higher affinity for TGF-β1 in comparison to TGF-β3 
(Figure 4). TGF-β1 was loaded and observed to be slowly 
released over 24 hours in alginate-FN hydrogels. In contrast, 
there was negligible release (and subsequent uptake) of TGF-
β1 in alginate-based chondrobags, in the absence of FN. The 
same conditions examined for TGF-β3 in FN-free 
chondrobags resulted in no detectable readings (Figure 4). 
TGF-β1 and TGF-β3 interactions with FN result in 
modulation of their parting from the alginate-FN microgel 
(solid phase) to the soluble phase, hence regulating their 
diffusion, and dissipation concentration locally and 
consequently influencing cell signalling. We showed that 
higher local concentrations of TGF-β1 in chondrobags are 
influenced by the presence of FN. We hypothesise that TGF-
β1 is bound to FN (FNIII12–14) and, given this occurs 
adjacent to the integrin binding region (FNIII9-10), provides 
the alginate-FN microgels with synergistic TGF-β1/integrin 
signalling leading into a highly permissive chondrogenic 
microenvironment 51 (Figure 2F). 
3.4 Quantification of gene expression in HACs and SSCs 
cultured chondrobags 
qPCR of chondrocyte-related marker transcripts was used 
to demonstrate the chondrogenic differentiation of SSCs 
(Figure 5K-T) and the phenotype maintenance of HACs 
(Figure 5A-J), following encapsulation within engineered 
alginate-FN chondrobags, with growth factors bound to FN 
and presented from a solid phase. The chondrogenic gene 
SOX9 has been observed during the in vitro induction of 
chondrogenesis and the subsequent promotion of the 
transcription of cartilage proteins, including type II collagen 
and aggrecan.52 Type II collagen (COL2A1) is the 
predominant collagen present in physiological hyaline 
cartilage, providing cartilage with tensile strength.53 Aggrecan 
(ACAN), the characteristic proteoglycan produced by 
chondrocytes, has been shown to link to collagen fibrils via 
hyaluronic acid. Importantly, the polyanionic nature of 
aggrecan draws water, which provides for cartilage expansion, 
key to the generation of mechanical function.54 
Expression of SOX9 (early marker), COL2A1 (mid/late 
marker) and ACAN confirmed the potential of alginate-FN 
chondrobags to maintain the chondrogenic phenotype of 
HACs. These markers showed no significant differences 
between chondrobags loaded with either GFs; despite TGF-β3 
Figure 4. TGF-β binding affinity for the full-length fibronectin (FN) in chondrobags. Infographic detailing the ELISA sample preparation. The following 
samples were collected at 1.5, 3, 6 and 24 hours; fibronectin-alginate with and without TGF-β1, FN-alginate with and without TGF-β3, alginate only with and 
without TGF-β1 as control, alginate only with and without TGF-β3 as control. (B) Optical density readings of TGF-β1. (C) Optical density readings of TGF-
β3. (D) Concentrations were calculated based on optical density and reconfirmed following GF uptake readings from medias with known GF concentrations. 
Significant binding over baseline (binding to BSA, value of 0.1, grey box in B) indicated (n = 6, means ± SD). *P = 0.001; Student’s t test. 
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not being bound to chondrobags with as high affinity as TGF-
β1 (Figure 4). Chondrogenic associated SOX9 expression was 
observed to be notably up-regulated in HACs loaded with 
TGF-β1 (4.1-fold change) and loaded with TGF-β3 (3.6-fold 
change) (Figure 5A). This was also observed for COL2A1: 
with TGF-β1 (111.4-fold change) and treated with TGF-β3 
(252.7-fold change) (Figure 5B), and ACAN: 8.5-fold change 
with TGF-β1 and 8.1-fold change treated with TGF-β3 (Figure 
5C). This cumulative increase in the expression of COL2A1 
and ACAN was in line with previous studies.22, 55  
In contrast, SSCs did not display a clear and significant 
differentiation along the chondrogenic lineage. However, 
several studies have identified a discrete decrease in aggrecan 
expression for cells cultured within a 3D construct, supporting 
the current findings using SSCs (Figure 5M). Only SOX9 
expression was significantly up-regulated following SSCs 
treatment with TGF-β1 (4.7-fold change) and treatment with 
TGF-β3 (4.6-fold change) (Figure 5K). 
There are a number of markers of hypertrophic 
chondrocytes, with collagen type X and MMP13 the most 
widely recognised.52, 56 Type X collagen functions as a 
substructure for ensuing matrix calcification.57 Hypertrophic 
ECM functionally differs to physiological hyaline cartilage 
and, is in part, comparable to bone matrix. In this context, the 
current studies indicate that following 28 days of 
chondrogenic differentiation, HACs in chondrobags with 
TGF-β1 bound to FN displayed reduced commitment to the 
formation of hypertrophic chondrocytes, compared to cells 
stimulated with TGF-β3 (Figure 5D-E). Strikingly, the current 
results observed using engineered chondrobags, with TGF-β1 
bound to FN, demonstrate negligible evidence of hypertrophic 
chondrocytes, enabling the maintenance of the required 
chondrocytic phenotype for cartilage tissue repair.  
Specific genes for proliferation and cell cycle58 were also 
examined. HACs and SSCs encapsulation in alginate-FN 
chondrobags resulted in modulation of essential components 
in G1/S, with decreased levels of p16 (CDKN2A), increased 
CDK6 and cyclin expression (CCDN1), resulting in enhanced 
cell cycle progression and proliferation (Figure 5H-J and 5R-
T). In the current study, we observed a significant up-
regulation of MKI67 in cells encapsulated in chondrobags 
with TGF-β1 bound to FN (5-fold change for HACs and 35-
fold change for SSCs) (Figure 5G and 5Q) and to TGF-β3 
(1.9-fold change for HACs and 1.5-fold change for SSCs) 
(Figure 5G and 5Q), indicating higher proliferative activity of 
cells within TGF-β3 alginate-FN chondrobags than cells 
within TGF-β1. 
TGF-β1 appears to be closely connected with cell growth 
and differentiation providing  a crucial role in the regulation 
of autocrine and paracrine processes.59 In addition, TGF-β1 is 
a growth modulator with multi-physiological potencies on 
immune suppression and inflammation, cell differentiation, 
Figure 5. Gene expression in HACs and SSCs cultured within chondrobags. Chondrogenic, hypertrophic, proliferation and cell cycle specific gene 
expression in primary human articular chondrocytes (HACs) (A-J) and primary human skeletal stem cells (SSCs) (K-T) cultured in the presence of TGF-β1 
or TGF-β3 for up to 28 days relative to untreated control. Differential expression of A-K: SOX9, B-L: COL2A1, C-M: ACAN, D-N: COL10A1, E-O: MMP13, 
F-P: PCNA, G-Q: MKI67, H-R: CCDN1, I-S: CDK6, J-T: CDKN2A analysed by qPCR. Values is the mean ± SD of triplicate determinations per sample. 
*p < 0.05, **p < 0.01, ***p < 0.001, one-way ANOVA. 
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wound healing and cancer.60 However, Mueller and 
colleagues failed to detect any differences between aggregates 
preconditioned with TGF-β1 and TGF-β3 following 
histological evaluation and quantification of ALP secretion.49 
The likely differences from our study reside with the 
observation that in the engineered chondrobags, TGF-β1 is 
also bound to FN and presented from a solid phase (Figure 4), 
with TGF-β1 more accessible to the encapsulated cells and 
thus favouring chondrogenic differentiation. 
3.5 microRNA profiling in HACs and SSCs cultured in 
chondrobags 
Small noncoding RNAs (19-24 nucleotides long) have 
gained significant research interest in recent years.61 
MicroRNAs (miRNAs) in particular are important regulators 
of gene expression.62 miRNAs are involved in the process of 
stem cell differentiation, together with stem cell therapy and 
can prompt skeletal regeneration and thus, miRNAs offer 
innovative approaches to prevent/treat OA and osteoporosis 
(OP)63. Following culture of HACs and SSCs with or without 
TGF- β1 or TGF- β3 for 28 days, TaqMan qPCR was used to 
determine the expression levels of miRNAs. miR-140 was 
employed as a positive control for chondrogenic 
differentiation.64 Chondrogenic related miR-140-3p 
expression was notably up-regulated in the encapsulated cells 
in TGF-β1 alginate-FN chondrobags (61.8-fold change for 
HACs and 1.7-fold change for SSCs) (Figure 6A and 6D) and 
TGF-β3 alginate-FN chondrobags (81.2-fold change for 
HACs and 3.4-fold change for SSCs) (Figure 6A and 6D). 
miR-140 is an important modulator of cartilage homeostasis 
and implicated in OA. Critically, miR-140 is almost uniquely 
and abundantly expressed in chondrocytes65 and, in addition, 
plays an important role in bone development, at least in part 
by controlling proliferation. Miyaki and collaborators reported 
that throughout chondrogenesis, miR-140 expression levels 
increase in differentiated human MSCs in comparison to 
undifferentiated MSC populations together with expression of 
COL2A1, ACAN and SOX9. These finding indicate miR-140 
is a marker and potential modulator of chondrogenesis.66  
In contrast, miR-146b expression was significantly down-
regulated in cells encapsulated in TGF-β1 alginate-FN 
chondrobags (0.8-fold change for HACs and 0.1-fold change 
for SSCs) (Figure 6B and 6E) and in TGF-β3 alginate-FN 
chondrobags (0.5-fold change for HACs and 0.2-fold change 
for SSCs) (Figure 6B and 6E). Compared to chondrobags 
cultured in basal media, miR-146b was down-regulated during 
chondrogenic differentiation of human bone marrow derived 
SSCs. Furthermore, we have previously shown that miR-146b 
serves as a negative modulator of chondrogenesis, with an 
important role in the regulation of SOX5 expression during the 
chondrogenic differentiation of human bone marrow derived 
SSCs.67  
miR-138 expression was observed to be notably up-
regulated in HACs encapsulated in TGF-β3 alginate-FN 
chondrobags (1.4-fold change) but not with TGF-β1 (0.95-
fold change) (Figure 6C). miR-138 expression in SSCs was 
significantly up-regulated under both conditions: 3.3-fold 
change with TGF-β1 and 4.8-fold change with TGF-β3 
(Figure 6F). These results demonstrate the commitment of 
HACs and SSCs following culture for 28 days in the 
chondrobags towards the chondrogenic lineage. The 
overexpression of miR-138 has been shown to inhibit 
osteoblast differentiation hMSCs in vitro. miR-138 inhibition 
serves as an antimiR-138 for promoting expression of 
osteoblast-specific genes as well as the activity of alkaline 
phosphatase (ALP) and matrix mineralization.68  
3.6 Histological analysis of collagen formation in 
chondrobags 
Chondrobags encapsulating HACs cultured in vitro for 28 
days in the presence of TGF-β1 or TGF-β3 indicated enhanced 
cell proliferation evidenced by increased collagen deposits 
with faint Sirius Red staining compared to control (Figure 7). 
This result correlated with the observation of growth and 
proliferation observed in Figure 3 as well as gene expression 
results for proliferation and cell cycle markers in Figure 5F-J. 
In contrast, intense Alcian Blue stating (but not Sirius Red 
staining) was observed in the matrix of chondrobags cultured 
in the presence of TGF-β3 (Figure 7C) as compared to TGF-
β1 (Figure 7B) indicating the formation of ECM (arrow). The 
comparatively intensive Alcian Blue staining of cartilage 
matrix and proteoglycans in chondrobags cultured in presence 
of TGF-β3 correlated with the observed gene expression 
studies of collagen II (COL2A1, Figure 5B) and collagen X 
(COL10A1, Figure 5D) from similarly treated samples. 
Safranin-O stains polyanions in alginate, 69 thus, the formation 
of new cartilage in the chondrobags can be difficult to 
determine. Nevertheless, the distribution of nuclei within the 
chondrobags can be clearly observed (Figure 7). The lack of 
fast green staining observed confirmed the absence of bone 
formation within these sections. 
Figure 6. microRNA profiling in HACs and SSCs cultured within 
chondrobags. miRNA expression in primary human articular chondrocytes 
(HACs) (A-C) and primary human skeletal stem cells (SSCs) (D-F) cultured in 
the presence of TGF-β1 or TGF-β3 for up to 28 days relative to untreated 
control. Differential expression of A-D: miR-140, B-E: miR-146b, C-F: miR-
138, analysed by TaqMan q-PCR. Values represent mean ± SD of duplicate 
determinations per sample. *p < 0.05, **p < 0.01, ***p < 0.001, one-way 
ANOVA. 
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4. Conclusion 
The current findings demonstrate that engineered TGF-β1 
alginate-FN chondrobags provide an appropriate biomimetic 
environment for the formation of hyaline cartilage in vitro. We 
demonstrate that TGF-β1 bound to FN and presented from a 
solid phase, facilitates and enhances chondrogenic 
differentiation. Importantly, TGF-β1 loaded chondrobags 
promote chondrogenesis without the formation of 
hypertrophic chondrocytes. This cue-integrated-3D 
biomaterial platform, demonstrated increased proliferation, 
enhanced cell viability, chondrogenic differentiation of SSCs 
in situ and phenotype maintenance for HACs. The current 
studies illustrate the potential applications for a TGF-β1 
alginate-FN chondrobags platform as a workable 3D 
bioprinting and culture system for cartilage tissue regeneration 
with therapeutic applications therein.  
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